Tag: Biotech and Pharma

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday.

Telehealth company Doximity’s quarterly earnings beat wasn’t enough to offset investors’ disappointment around its guidance for the coming fiscal year.

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

Αύξηση κατά 32,4% παρουσιάζουν τα συνολικά κέρδη προ φόρων, τόκων και αποσβέσεων (EBITDA) του Ομίλου Lavipharm για το Α’ τρίμηνο του 2025, τα οποία διαμορφώθηκαν σε 3,77 εκατ. ευρώ έναντι 2,85 εκατ. κατά το αντίστοιχο διάστημα του προηγούμενου έτους.

Eli Lilly (LLY.N),  said on Sunday its drug Zepbound was superior to Novo Nordisk’s (NOVOb.CO),  Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.

U.S. President Donald Trump plans to sign an executive order on prescription drug pricing on Monday that aims to align the United States with what other countries pay, a move he said on social media would be a cut of 59%.

Novo Nordisk NVO stock rose after the Danish pharma giant posted better-than-expected quarterly earnings even as sales of its blockbuster drugs Ozempic and Wegovy slowed, but cut its guidance for the year.

Moderna on Thursday reported first-quarter profit and sales that beat Wall Street estimates, helped by the company’s cost-cutting efforts following waning post-pandemic demand for its COVID-19 vaccine.

Eli Lilly (LLY)+1.55% stock was falling early Thursday even as the drugmaker posted first-quarter earnings above analysts’ expectations, driven by higher sales of its blockbuster weight-loss drugs Zepbound and Mounjaro.

The U.S. Food and Drug Administration has approved Johnson & Johnson’s (JNJ.N),  drug to treat some patients aged 12 years and older with an immune-mediated disorder, the drugmaker said on Wednesday.

Hims & Hers stock HIMS+1.39% jumped after the telehealth company that has built a business around selling copycat weight-loss drugs announced a deal with Ozempic-maker Novo Nordisk.

Pfizer PFE +0.57% reported earnings that beat Wall Street expectations early Tuesday, but said it is “unable to predict” tariff-related impacts “at this time.”

Merck KGaA (MRCG.DE),  has struck a deal to buy U.S. biotech company SpringWorks Therapeutics (SWTX.O),  for an equity value of $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to expiring patents.

AbbVie (ABBV +3.15%) gave investors reason to cheer, reporting higher earnings than expected for a fifth straight quarter and raising its financial forecasts for the year.

The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Its latest financial results late Thursday should reinforce its position

Οι επενδύσεις μας αποδίδουν και ενισχύουν σημαντικά την κερδοφορία μας. Μετά από 18 χρόνια ανταμείβουμε τους μετόχους για την εμπιστοσύνη τους, διανέμοντας μέρισμα (2 λεπτά/ανά μετοχή)», δήλωσε ο CFO του ομίλου.

Bristol Myers Squibb reported better-than-expected earnings for the first quarter and boosted its outlook while noting the impact of stiff competition in the pharmaceutical market.

Bristol Myers Squibb’s Cobenfy as an adjunctive treatment did not reach the threshold for a statistically significant difference compared to a placebo with an atypical antipsychotic in adults with schizophrenia.

Swiss pharmaceutical giant Roche on Tuesday said that it would invest $50 billion in the U.S. over the next five years, amid concerns about the impact of possible new White House tariffs on pharma goods from abroad.

Eli Lilly (LLY.N),  said on Thursday its experimental pill, orforglipron, led to weight loss of nearly 8% at the highest dose and lowered blood sugar in patients with type 2 diabetes in a late-stage trial.